A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05543629. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of BMS-986442 in Combination With Nivolumab or Nivolumab and Chemotherapies in Participants With Advanced Solid Tumors and Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate BMS-986442 in combination with nivolumab (with or without chemotherapy) for its antitumor efficacy and benefit to participants.
Study identification
- NCT ID
- NCT05543629
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 36 participants
Conditions and interventions
Conditions
Interventions
- BMS-986442 Biological
- Nivolumab Biological
- Docetaxel Drug
- Carboplatin Drug
- Pemexetred Drug
- Paclitaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 3, 2022
- Primary completion
- Sep 11, 2024
- Completion
- Sep 11, 2024
- Last update posted
- Mar 17, 2025
2022 – 2024
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic in Arizona - Phoenix | Phoenix | Arizona | 85054 | — |
| Local Institution - 0096 | Costa Mesa | California | 92627 | — |
| Local Institution - 0075 | Orange | California | 92868-3201 | — |
| Mayo Clinic in Florida | Jacksonville | Florida | 32224 | — |
| Local Institution - 0027 | Orlando | Florida | 32804 | — |
| Local Institution - 0029 | Fort Wayne | Indiana | 46804 | — |
| Local Institution - 0022 | New Orleans | Louisiana | 70121 | — |
| Local Institution - 0005 | Grand Rapids | Michigan | 49546 | — |
| Mayo Clinic in Rochester, Minnesota | Rochester | Minnesota | 55905 | — |
| Local Institution - 0003 | Hackensack | New Jersey | 07601 | — |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | — |
| Local Institution - 0019 | Cincinnati | Ohio | 45219 | — |
| Local Institution - 0046 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0016 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05543629, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 17, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05543629 live on ClinicalTrials.gov.